AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$AXSM

Axsome Therapeutics stock rises 2% on beat driven by strong product growth

Axsome Therapeutics (NASDAQ:AXSM) reported Q3 2025 revenue of $259.7M, up 52% YoY, beating estimates. Shares rose 2.13% premarket. EPS loss was -$0.25, better than expected. Growth driven by AUVELITY and SUNOSI sales. R&D and SG&A expenses increased. Company announced new trials and regulatory targets.

Original reporting
investing.com
Published Nov 2, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AXSM
Bullish
high confidence
Mentioned
$AXSM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AXSMBullishHigh
01

Why it matters

The earnings surprise and product growth are likely to lift the stock in the short term, while upcoming trial readouts add longer‑term risk/reward considerations.

02

Market read

Earnings beat provides a fresh catalyst for AXSM, with potential spillover to the biotech sector.

03

What to watch

Upcoming Phase 3 trial results for AXS‑05 and NDA timeline for AXS‑12 could introduce volatility.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Axsome Therapeutics reported a strong Q3 earnings beat, driven by its AUVELITY and SUNOSI products, and announced upcoming clinical milestones.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Q3 2025 results beat estimates with revenue $259.7M (+52% YoY) and EPS beat, driving a 2% pre‑market rise.

Expected impact

likely upward pressure as investors price in the revenue beat and product momentum

Evidence & confidence

The company posted a surprise earnings beat and highlighted double‑digit growth in its lead products, prompting a pre‑market rally.

Market effects

Sector

Positive signal for biotech and specialty pharma peers, especially those with CNS pipelines.

Regional

U.S. biotech sector may see modest gains in early trading.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

The beat may be priced in quickly, and higher R&D spend could pressure margins.

Key entities

  • company
    Axsome Therapeutics Inc.

    Biopharma company reporting earnings beat.

Read at source← All news

StoryAxsome reports strong Q3 growth as AUVELITY sales accelerate

Also covered by

3 outlets

Related articles

NOV 2
$AXSMMedAI 8/10

Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary

Axsome Therapeutics reported Q3 2026 revenue growth of 52% YoY, driven by AUVELITY's performance in MDD and ADA, with total revenue surpassing $1B annually. Net loss narrowed to $12.9M due to operating leverage. AUVELITY saw sequential growth, with primary care prescribers being a key driver. The company maintained a gross margin in the low to mid-90% range. Management expects continued growth and sufficient cash to reach cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMedAI 8/10

Axsome (AXSM) Q3 2026 Earnings Call Transcript

Axsome (AXSM) reported Q3 2026 revenue of $260M, up 52% YoY. AUVELITY sales grew 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company highlighted strong prescription growth for AUVELITY, particularly in Alzheimer's agitation and major depressive disorder indications, and expects continued momentum. SYMBRAVO sales also grew 88% YoY to $3.9M. The company maintains a strong cash position and anticipates cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMed

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call

Axsome Therapeutics reported Q3 earnings, with R&D expenses rising to $50.6M and SG&A to $203.1M. AUVELITY prescriptions grew 40% YoY, while SYMBRAVO and SUNOSI also saw increases. The company expects cash to fund operations until cash-flow positivity. Axsome outlined 2027 milestones, including FDA review of AXS-12 and trials for AXS-05, solriamfetol, and AXS-20.

finance.yahoo.com2 min